Design, synthesis, and evaluation of isoquinoline ureas as TRPV1 antagonists.
Inhibition of transient receptor potential vanilloid receptor 1 (TRPV1) has emerged as a novel approach in the treatment of various pain states. Pyrrolidinyl urea, SB 705498 with pKb = 7.3 in guinea pig TRPV1 receptor has been investigated in Phase II clinical trials for pain and chronic cough. Another heteroaryl urea derivative, A-425619 1, has been reported to be a potent and selective TRPV1 antagonist of capsaicin-evoked receptor activation with an IC50 value of 4 nM in hTRPV1. A series of thirteen A-425619 1 analogues with modifications centered around the C-region was synthesized to understand the binding site characteristics of TRPV1 receptors. We synthesized a series of isoquinoline ureas and evaluated their antagonist potency using smooth muscle assay using guinea pig trachea along with evaluation of the molecular properties and molecular modeling using CoMFA studies. p-Chloro 4, p-bromo 5, m-isothiocyanate 15, and p-isothiocyanate 16 derivatives were found to be the most potent members of the series with pKb values in the range of 7.3-7.4 in the functional assay using guinea pig trachea. The lead compound A-425619 1 exhibited a pKb value of 8.1 in this assay. The para-substituted analogues were found to be more potent than the ortho- and meta- analogues in biological assay. This observation was further supported by molecular modeling studies using CoMFA.